PMC8762285_01
Enhanced MRI scans in head. (A) Enhanced MRI before the treatment of durvalumab. (B) Enhanced MRI revealed the diffuse abnormal signal after a 11-cycle monotherapy maintenance therapy with durvalumab. (C) Enhanced MRI revealed an improved condition after 21 days treatment of methylprednisolone. (D) Enhanced MRI indicated that the diffuse abnormal signal was disappeared after 3 months.
fphar-12-799728-g001.jpg
PMC8762285_01_fphar-12-799728-g001.jpg
F1
The patient was initially treated with six cycles of EP (Etoposide + Nedaplatin) program (Etoposide 170mg, d1-3, Nedaplatin 140mg, d1) combined with durvalumab (500 mg) chemotherapy (Figure 1A), and chest computed tomography (CT) scan confirmed a partial response. Enhanced magnetic resonance imaging (MRI) found the diffuse abnormal signal in both head and spinal cord (Figures 1B, 2A). After 21 days, the demyelinating lesions were improved than before (Figures 1C, 2B), and the dose of methylprednisolone was gradually reduced until it was stopped. Three months later, Enhanced MRI indicated that the diffuse abnormal signal was disappeared (Figures 1D, 2C), and the symptoms of numbness and fatigue of the patient's limbs were completely disappeared.
Enhanced MRI scans in spinal cord. (A) Enhanced MRI before the treatment of methylprednisolone. (B) Enhanced MRI revealed an improved condition after the treatment of methylprednisolone. (C) Enhanced MRI revealed a disappeared diffuse abnormal signal after 3 months.
fphar-12-799728-g002.jpg
PMC8762285_01_fphar-12-799728-g002.jpg
F2
Enhanced magnetic resonance imaging (MRI) found the diffuse abnormal signal in both head and spinal cord (Figures 1B, 2A). After 21 days, the demyelinating lesions were improved than before (Figures 1C, 2B), and the dose of methylprednisolone was gradually reduced until it was stopped. Three months later, Enhanced MRI indicated that the diffuse abnormal signal was disappeared (Figures 1D, 2C), and the symptoms of numbness and fatigue of the patient's limbs were completely disappeared.
Timeline of treatment administration from the episode of care.
fphar-12-799728-g003.jpg
PMC8762285_01_fphar-12-799728-g003.jpg
F3
The timeline treatment administration from the episode of care was presented in Figure 3.